WILMINGTON, Del., Dec. 07, 2016 -- Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of holders of Chemtura Corporation (“Chemtura”) (NYSE:CHMT) common stock in connection with the proposed acquisition of Chemtura by Lanxess Deutschland GmbH (“Lanxess”) announced on September 26, 2016 (the “Complaint”). The Complaint, which alleges violations of the Securities Exchange Act of 1934 against Chemtura, its Board of Directors (the “Board”), and Lanxess, is captioned Scarantino v. Chemtura Corporation, Case No. 2:16-cv-06051-ER.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Seth D. Rigrodsky or Gina M. Serra, at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail at [email protected]; or at: http://rigrodskylong.com/investigations/chemtura-corporation-chmt/.
On September 25, 2016, Chemtura entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lanxess. Pursuant to the Merger Agreement, Lanxess will acquire Chemtura, and Chemtura shareholders will receive $33.50 per share in cash for each share of Chemtura that they own (the “Proposed Transaction”).
The Complaint alleges that, in an attempt to secure shareholder support for the Proposed Transaction, on November 4, 2016, defendants issued materially incomplete disclosures in a Proxy Statement (the “Proxy Statement”) filed with the United States Securities and Exchange Commission. The Proxy Statement, which recommends that Chemtura stockholders vote in favor of the Proposed Transaction, omits material information necessary to enable shareholders to make an informed decision as to how to vote on the Proposed Transaction, including material information with respect to the process and events leading up to the Proposed Transaction and the opinions and analyses of Chemtura’s financial advisor.
Plaintiff seeks injunctive and equitable relief and damages on behalf of holders of Chemtura common stock.
If you wish to serve as lead plaintiff, you must move the Court no later than February 5, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation, and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Seth D. Rigrodsky Gina M. Serra (888) 969-4242 (302) 295-5310 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com


RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Apple Turns 50: From Garage Startup to AI Crossroads
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 



